142,214 Shares in Arvinas, Inc. $ARVN Purchased by GSA Capital Partners LLP
GSA Capital Partners LLP recently purchased 142,214 shares of Arvinas, Inc. (NASDAQ:ARVN) valued at approximately $1.18 million, as disclosed in their latest 13F filing. Other institutional investors also adjusted their holdings, with several significantly increasing their stakes. Arvinas recently reported strong quarterly earnings, surpassing analyst expectations for both EPS and revenue, and several analysts have updated their ratings and price targets for the stock.
D. E. Shaw adjusts Arvinas (ARVN) stake as one entity falls below 5%
D. E. Shaw & Co. has adjusted its ownership in Arvinas, Inc. (ARVN), with D. E. Shaw & Co., L.P. and David E. Shaw each reporting a 5.4% beneficial ownership. Notably, D. E. Shaw & Co., L.L.C. has fallen below the 5% threshold, now holding 4.7% of the common stock. All reported beneficial ownership involves shared voting and dispositive powers through affiliated investment vehicles.
Enterprise value to EBITDA forward of Arvinas, Inc. – NASDAQ:ARVN
The article focuses on the enterprise value to EBITDA forward of Arvinas, Inc. (NASDAQ: ARVN), providing financial information and market data for the company. It appears to be a financial data page from TradingView, indicating that the market was closed with no trades at the time of viewing.
ARVN Maintains by Evercore ISI Group -- Price Target Lowered to $14.00
Evercore ISI Group has maintained an Outperform rating for Arvinas (ARVN) but lowered its price target from $19.00 to $14.00, reflecting a cautious outlook. Despite being significantly undervalued by GuruFocus's GF Value™ at $31.53 versus a current price of $8.95, the company faces financial challenges, high P/E ratios, and negative insider sentiment. Investors are advised to exercise caution and conduct thorough research due to the discrepancy between potential undervaluation and current financial indicators.
ARVN Maintained by Citigroup -- Price Target Lowered to $21.00
Citigroup has maintained a Buy rating for Arvinas (ARVN) but lowered its price target from $24.00 to $21.00, reflecting a 12.50% decrease. Despite this adjustment and concerns over profitability and insider selling, GuruFocus indicates ARVN is significantly undervalued with a GF Value™ of $31.53 against its current price of $9.01. The company shows strong growth potential but faces valuation and insider confidence challenges.
Arvinas, Inc. Stock 12‑Month Price Target Cut to $13.93, Implies 59% Upside
Arvinas, Inc.'s average 12-month price target has been lowered from $14.23 to $13.93 by 14 analysts, with forecasts ranging from $6 to $21 per share. This new target suggests a potential upside of approximately 59% from the Aug. 7 closing price. The consensus rating among 16 analysts remains "Buy," comprising 7 Buys, 8 Holds, and 1 Sell recommendation.
Morgan Stanley Adjusts Price Target on Arvinas to $10 From $11, Maintains Equalweight Rating
Morgan Stanley has lowered its price target for Arvinas (ARVN) to $10 from $11, while maintaining an Equalweight rating on the stock. This adjustment comes amidst other analyst activities concerning Arvinas, including Wedbush also adjusting its price target. The company, a clinical-stage biotechnology firm, continues to develop protein degradation therapies.
Precision Trading with Arvinas Inc. (ARVN) Risk Zones
This article provides a detailed AI-driven analysis for Arvinas Inc. (ARVN), highlighting potential trading strategies based on sentiment and risk zones. It outlines long, breakout, and short strategies with specific entry points, targets, and stop losses. The analysis also includes multi-timeframe signal strengths and support/resistance levels to assist in precision trading.
Precision Trading with Arvinas Inc. (ARVN) Risk Zones
This article provides a detailed analysis of Arvinas Inc. (NASDAQ: ARVN) focusing on precision trading strategies generated by AI models. It highlights a significant risk-reward setup with a potential 31.0% gain versus 0.3% risk, along with specific entry zones, targets, and stop losses for position trading, momentum breakout, and risk hedging strategies. The analysis also includes multi-timeframe signal strengths and support/resistance levels.
Price to book forward of Arvinas, Inc. – NASDAQ:ARVN
This article provides a financial metric, "Price to book forward," for Arvinas, Inc. (NASDAQ:ARVN). It appears to be a stub or a data point from a financial platform, showing the company's ticker, market, and a period value, but without further elaboration or detailed financial data. The content primarily consists of navigation and platform information from TradingView.
Arvinas (NASDAQ:ARVN) Rating Increased to Hold at Wall Street Zen
Wall Street Zen has upgraded Arvinas (NASDAQ:ARVN) from a "Sell" to a "Hold" rating. This upgrade comes despite mixed analyst sentiments and a forecast for a full-year loss, following a significant quarterly earnings beat where Arvinas reported $2.58 EPS against expected a $0.37 loss and revenue exceeding expectations by over 1,000%. The company's stock, however, remains below its 52-week high, trading at $8.75.
Arvinas Inc (ARVN) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Arvinas Inc (ARVN), indicating its current earnings forecast score, average price target, and analyst ratings. Based on 17 analysts, the stock has a "Buy" trend with a target price of $14.00, suggesting a potential upside of 61.90%. The article also includes expected revenue and EPS for upcoming quarters and highlights past performance compared to market expectations.
Arvinas posts corporate presentation highlighting PROTAC degrader pipeline in oncology and neurology
Arvinas recently released a corporate presentation that highlights its PROTAC degrader pipeline, focusing on advancements in oncology and neurology. Key updates include the FDA clearance of VEPPANU for advanced breast cancer and the out-licensing of luxdegalutamide to Novartis, generating over $800 million in non-dilutive cash and extending Arvinas's cash runway into the second half of 2028. Novartis is currently conducting three Phase 2 trials for luxdegalutamide in metastatic prostate cancer settings.
Arvinas Inc (ARVN) Stock News Today
This article provides a current snapshot of Arvinas Inc (ARVN) stock information. It includes the latest stock price, market capitalization, and a note indicating that more news, earnings, and analyst ratings are coming soon. The page serves as a placeholder for future updates on ARVN.
Enterprise value to revenue forward of Arvinas, Inc. – NASDAQ:ARVN
This article provides a financial snapshot for Arvinas, Inc. (NASDAQ: ARVN), focusing on its enterprise value to revenue forward. It appears to be a financial data point from TradingView, showing the period, value, and change for this specific metric. The content itself is very minimal, presenting only the metric's title and placeholders for its values.
Arvinas (NASDAQ:ARVN) Trading Down 7.8% on Analyst Downgrade
Arvinas (NASDAQ:ARVN) shares dropped 7.8% after Wells Fargo downgraded the stock from "overweight" to "equal weight." Despite this, the company reported a significant second-quarter beat with EPS of $2.58 and revenue of $249.7 million, largely due to licensing and milestone activities. Arvinas also received approval for VEPPANU, its first PROTAC protein degrader, and anticipates clinical data from three Phase 1 programs within the next year.
Arvinas Q2 2026 earnings: Licensing revenue drives a return to profit
Arvinas (ARVN) reported a significant turnaround in Q2 2026, driven by a surge in licensing revenue from its collaboration with Pfizer and the Rigel license agreement, leading to a profit of $2.58 diluted EPS. The company's revenue reached $249.7 million, up from $22.4 million a year earlier, and operating expenses decreased, primarily due to lower R&D spending. Despite the accounting-driven profit, Arvinas experienced cash consumption in operations during the first half of 2026, though its cash reserves are projected to fund operations into the second half of 2028.
Arvinas (ARVN) Stock Jumps As Profit Windfall Sparks Durability Debate
Arvinas (ARVN) stock surged 11.7% after reporting Q2 earnings, driven by a significant profit from licensing and collaboration revenue. Despite this windfall, concerns remain about the durability of its profit, as much of it was from one-off payments rather than recurring income, leading to a debate about the long-term stability of its milestone-heavy business model. The company's pipeline is becoming more concentrated, and key readouts for future programs are not expected until beyond 2026.
Arvinas (ARVN) holder Noah C. Berkowitz plans sale of 30,000 shares
Noah C. Berkowitz, a shareholder of Arvinas (ARVN), has filed notice to sell 30,000 shares of common stock for an approximate aggregate price of $264,000 through Morgan Stanley. The filing also disclosed a previous sale of 24,000 shares on July 9, 2026, for $201,528. Additionally, two tranches of restricted stock, totaling 30,000 shares, are scheduled to vest in May and July 2026 as compensation for services.
Arvinas (NASDAQ: ARVN) posts $169.4M profit on VEPPANU and Rigel deals
Arvinas (NASDAQ: ARVN) reported a significant financial turnaround in Q2 2026, posting a net income of $169.4 million and revenue of $249.7 million, compared to a net loss of $61.2 million and $22.4 million revenue in Q2 2025. This profitability was largely driven by collaboration and licensing revenues related to VEPPANU (vepdegestrant), including deals with Pfizer and Rigel Pharmaceuticals. The company's cash reserves stood at $567.9 million, projected to fund operations into the second half of 2028, and they continue to advance multiple PROTAC degrader programs in oncology and neurology.
ARVINAS, INC. 2026: Revenue $249.7M, EPS $2.58— 10-Q Summary
ARVINAS, INC. reported significant financial growth in 2026, with revenue reaching $249.7M and diluted EPS at $2.58, largely driven by licensing and milestone recognition. Key business highlights include FDA approval for VEPPANU and its out-license to Rigel, leading to substantial upfront and milestone payments. The company also advanced multiple clinical programs and optimized operations through workforce reductions.
Arvinas, Inc. Stock 12‑Month Price Target Cut to $14.85, Implies 84% Upside
Arvinas, Inc.'s average 12-month price target has been lowered from $15.08 to $14.85 by 13 analysts, with individual forecasts ranging from $6 to $24. This updated target suggests an 84% potential upside based on the Aug. 3 closing price. Despite the price target cut, the consensus rating from 15 analysts remains a "Buy," with 7 Buys, 7 Holds, and 1 Sell recommendation.
BTIG reiterates Arvinas stock Buy rating on pipeline execution
BTIG reiterated a Buy rating and an $18.00 price target on Arvinas Inc. (NASDAQ:ARVN) following the company's strong second-quarter earnings report. Arvinas reported significant GAAP revenue of $249.7 million and a cash position of $567.9 million, providing runway into the second half of 2028. The company is advancing several clinical programs with key data readouts and trial initiations expected in late 2026 and 2027.
Wedbush Adjusts Price Target on Arvinas to $12 From $11, Maintains Neutral Rating
Wedbush has increased its price target for Arvinas (ARVN) to $12 from $11, while maintaining a Neutral rating on the stock. This adjustment comes as Arvinas continues to advance its PROTAC protein degrader platform and multiple investigational drugs through clinical development.
Arvinas (NASDAQ:ARVN) Trading 14.8% Higher Following Better-Than-Expected Earnings
Arvinas (NASDAQ:ARVN) saw its shares surge 14.8% after reporting better-than-expected quarterly earnings and revenue. The company beat consensus EPS estimates by $2.95 and reported a 1,014.7% year-over-year revenue increase. Despite mixed analyst ratings, the stock holds a consensus Hold rating with a target price of $15.42.
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
Arvinas, Inc. (ARVN) reported Q2 earnings of $2.58 per share, significantly beating the Zacks Consensus Estimate of a $0.24 loss per share, and revenues of $249.7 million, exceeding estimates by 562.56%. Despite this strong performance, the stock has underperformed the S&P 500 year-to-date, and currently holds a Zacks Rank #3 (Hold). The company's future performance will depend on management's outlook and industry trends.
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
Arvinas, Inc. (ARVN) reported Q2 earnings of $2.58 per share, significantly surpassing the Zacks Consensus Estimate of a $0.24 loss and year-ago loss of $0.84. The company's revenue reached $249.7 million, beating estimates by 562.56% and showing substantial growth from $22.4 million a year prior. Despite strong Q2 results, Arvinas shares have declined 32% year-to-date, contrasting with the S&P 500's 11% gain.
Transcript: Arvinas Q2 2026 Earnings Conference Call
Arvinas (NASDAQ: ARVN) reported its Q2 2026 earnings, highlighting significant strategic milestones including FDA approval of their first PROTAC degrader, Vepanu, and an out-licensing deal with Rigel Pharmaceuticals. The company announced $249.7 million in revenue for the quarter and a strong cash position of $567.9 million, projecting financial stability through 2028. Arvinas plans to advance its oncology and neurology pipeline, with key clinical data expected in the next 12 months for ARV393 (BCL6 degrader), ARV027 (SBMA), and ARV102 (LRRK2 degrader for PSP/PD).
FDA approves first PROTAC therapy as Arvinas licenses VEPPANU
Arvinas (Nasdaq: ARVN) reported strong Q2 2026 financial results, with revenue soaring to $249.7 million due to the FDA approval and out-licensing of VEPPANU, the first-ever PROTAC degrader. VEPPANU, approved for ER+/HER2-, ESR1-mutated advanced breast cancer, was licensed to Rigel Pharmaceuticals for global development and commercialization. The company also provided updates on its diverse pipeline of PROTAC programs, including ARV-393, ARV-102, ARV-027, and the initiation of a new immuno-oncology trial for ARV-6723, and confirmed a cash runway into the second half of 2028.
Arvinas reports $249.7M Q2 revenue, $169.4M net income and guidance into H2 2028
Arvinas reported strong financial results for Q2 2026, with revenue of $249.7 million and net income of $169.4 million, largely due to collaboration and licensing agreements. The company announced that its cash reserves of $567.9 million are sufficient to fund operations into the second half of 2028. Key business highlights include the FDA approval of VEPPANU and its subsequent licensing to Rigel, along with significant progress in its clinical pipeline with several upcoming data milestones.
Earnings To Watch: Arvinas Inc (ARVN) Q2 2026 -- GF Value Sees 34% Upside
Arvinas Inc (ARVN) is preparing to release its Q2 2026 earnings on August 4, 2026, with analysts forecasting $32.54 million in revenue and an EPS of -$0.44. Despite missing previous quarter's estimates, the GF Value suggests a 34.37% upside from its current price, and brokerage firms rate it as "Outperform." Revenue and earnings estimates for the full year 2026 have seen adjustments in the past 90 days.
Price to sales forward of Arvinas, Inc. – NASDAQ:ARVN
This article provides financial information for Arvinas, Inc. (NASDAQ: ARVN), specifically focusing on its forward price-to-sales ratio. It indicates that the market was closed at the time of publication and no trades were made. The content is part of a larger financial data platform.
Arvinas Inc (ARVN) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Arvinas Inc (ARVN), noting its current valuation score of 6.66 within the Biotechnology & Medical Research industry. It details the company's current P/E ratio, contrasting it with recent highs and lows. The report also indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by Arvinas Inc.
Arvinas (ARVN) Projected to Announce Quarterly Earnings on Wednesday
Arvinas (ARVN) is expected to report its Q2 2026 earnings before market open on Wednesday, August 5th, with analysts projecting a loss of $0.24 per share and revenue of $60.7 million. The company's previous quarter showed a narrower-than-expected loss of $0.90 per share despite a significant year-over-year revenue decrease. ARVN currently holds a consensus "Hold" rating from analysts with an average price target of $15.42, and institutional investors own a substantial majority of the stock.
ARVN|Arvinas Inc|Price:8.230|Chg%:+0.030
This article provides a comprehensive stock analysis of Arvinas Inc (ARVN), highlighting its healthy fundamentals, significant growth potential, and "fairly valued" status. It notes high institutional ownership and multiple "Buy" ratings from analysts, despite a medium-term expectation for the stock price to trend down and average performance over the past month. The company specializes in PROTAC protein degrader therapies, with several investigational drugs in clinical development.
Arvinas Inc (ARVN) Institutional Confidence
Arvinas Inc (ARVN) has an institutional shareholding score of 7.00, placing it 80th out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 83.59%, which is a 50.35% decrease quarter-over-quarter. Bill Nygren | OAKMX is the largest institutional shareholder, holding 0.44% of shares outstanding despite a 38.89% decrease in holdings.
Technical Reactions to ARVN Trends in Macro Strategies
This article provides a technical analysis of Arvinas Inc. (NASDAQ: ARVN), highlighting a neutral near-term sentiment with potential for moderate mid-term weakness. It identifies a significant risk-reward setup targeting a 30.2% gain versus a 0.3% risk. The analysis also details institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
Arvinas, Inc. (Nasdaq: ARVN) announced it will report its second quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, August 4, 2026, at 8:00 a.m. ET. The webcast will be available on the investor page of the Arvinas website with a replay accessible thereafter. Arvinas is a biotechnology company focused on developing PROTAC-based protein degradation therapies for various diseases.
Arvinas to give corporate update during Aug. 4 webcast
Arvinas (Nasdaq: ARVN) announced it will host a live webcast on August 4, 2026, at 8:00 a.m. ET, to discuss its second-quarter 2026 financial results and provide a corporate update. The biotechnology company, known for its PROTAC protein degrader platform and co-development of the first FDA-approved PROTAC with Pfizer, is advancing multiple investigational drugs for various disorders. Investors can access the event and its replay via the "Events and Presentations" section of Arvinas's investor webpage.
Arvinas Inc (ARVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Arvinas Inc (ARVN), focusing on business segments and regional contributions. However, it notes that relevant data for FY2025 (Q1-Q4) and FY2024-2023 has not yet been disclosed by the company, though it lists US revenue at $262.60M with 0.00% proportion. The page also displays current stock information and market capitalization for Arvinas Inc.
Arvinas, Inc. $ARVN is Rangeley Capital LLC's 8th Largest Position
Rangeley Capital LLC reduced its stake in Arvinas, Inc. (NASDAQ:ARVN) by 43.4% in the first quarter, making the stock its 8th largest holding. Despite this, institutional investors and hedge funds own 95.19% of the company. Arvinas reported a quarterly loss of $0.90 per share, outperforming estimates, but revenue saw a significant year-over-year decline. The company currently has a mixed analyst sentiment with a consensus "Hold" rating and an average price target of $15.42.
Arvinas (NASDAQ:ARVN) Upgraded at Wall Street Zen
Wall Street Zen upgraded Arvinas (NASDAQ:ARVN) from a "strong sell" to a "sell," while other analysts maintain a "Hold" consensus with an average target price of $15.42. The biopharmaceutical company recently reported a smaller-than-expected quarterly loss but saw a sharp decline in revenue, and company executives have been selling shares. The stock is currently trading at $8.03, below its 52-week high of $14.51.
TradingKey
This article provides a detailed quarterly and annual income statement for Arvinas Inc (ARVN), offering insights into its financial performance, including revenue, operating expenses, and net income. It presents a comprehensive historical data series for various financial metrics, along with an FAQ section explaining how to interpret the income statement and key metrics for stock analysis. The data highlights a recent change in total revenue for FY2026Q1, decreased by 91.74%.
Arvinas Inc (ARVN) Balance Sheet
This article provides a detailed quarterly and annual balance sheet for Arvinas Inc (ARVN), allowing users to evaluate financial health, analyze fundamentals, and calculate key ratios. It includes data on various assets, liabilities, and shareholders' equity components, along with FAQs explaining important balance sheet metrics and specific figures for Arvinas Inc.
Caxton Associates LLP Decreases Stake in Arvinas, Inc. $ARVN
Caxton Associates LLP reduced its stake in Arvinas, Inc. by 42.8% in the first quarter, selling 194,501 shares to hold 260,016 shares valued at $2.76 million. This reduction comes amid mixed Wall Street sentiment, with a "Hold" consensus rating and recent insider sales by the CEO and another executive. Arvinas reported a narrower-than-expected quarterly loss but significant year-over-year revenue decline.
Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Rating of "Hold" from Analysts
Arvinas, Inc. (NASDAQ:ARVN) has received a consensus "Hold" rating from thirteen analysts, with an average 12-month price target of $15.42. The company's stock is currently trading around $8.03, below its 200-day moving average. Despite reporting a smaller-than-expected loss in its latest quarterly results, revenue declined significantly year-over-year, and analysts forecast continued losses for the current year.
Arvinas, Inc. Revenue Breakdown – NASDAQ:ARVN
Arvinas, Inc. (NASDAQ: ARVN) generated $262.60 million USD in revenue last year, primarily from its Protein Degradation Therapies segment. This segment contributed the entirety of the revenue, which came mainly from the United States. The current year's revenue shows a slight decrease compared to $263.40 million USD in the previous year.
ARVN|Arvinas Inc|Price:8.030|Chg%:-0.090
Arvinas Inc. (ARVN) is a clinical-stage biotechnology company focused on developing protein degradation therapies. The company's stock is currently priced at $8.030, reflecting a -1.11% change from its previous close. Despite recent average stock market performance, its fundamentals are considered healthy with significant growth potential, although its valuation is seen as fairly valued within the Biotechnology & Medical Research industry.
Arvinas (ARVN) AGM 2026 Summary
This article summarizes Arvinas's (ARVN) 2026 Annual General Meeting (AGM), which was held virtually on June 24, 2026. Key outcomes included the approval of Class II directors, the passage of an advisory vote on executive compensation, and the ratification of Deloitte & Touche LLP as auditor. The summary also highlights recent company events, including study updates, conference presentations, and financial results.
Arvinas (ARVN) Proxy filing Summary
Arvinas (ARVN) released a summary of its proxy filing, detailing the upcoming annual meeting on June 24, 2026. Shareholders will vote on director elections, executive compensation, and the ratification of Deloitte & Touche LLP as the independent auditor. The board recommends voting for all proposals, and specifics for director nominations and shareholder proposals for the 2027 meeting are provided.
